Jurij Hanžel (Jurij Hanzel)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 36

Top Topics

Systematic Review

Patients With Inflammatory Bowel Disease

Ulcerative Colitis

Rheumatoid Arthritis Patients

Top Venues

Journal of Crohn's & colitis

Alimentary pharmacology & therapeutics

Medicina (Kaunas, Lithuania)

Inflammatory bowel diseases

This page only lists publications with an associated author ORCID identifier.

Publications

Špela Pintar, Jurij Hanžel, David Drobne, Matic Koželj, Tina Kurent, Nataša Smrekar, Gregor Novak
Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease. Medicina (Kaunas, Lithuania) 60 (2) (2024)
Charlotte Wong, Joep van Oostrom, Valérie Pittet, Peter Bossuyt, Jurij Hanžel, Mark A Samaan, Monika Tripathi, Wladyslawa Czuber-Dochan, Burisch J, Salvatore Leone, Roberto Saldaña, Filip Baert, Uri Kopylov, Susanna Jaghult, Michel Adamina, Krisztina Gecse, Naila Arebi
Baseline Data and Measurement Instruments Reported in Observational Studies in Inflammatory Bowel Disease: Results from a Systematic Review. Journal of Crohn's & colitis 18 (6) (2024)
Florian Rieders, Christopher Ma, Jurij Hanžel, Joel G Fletcher, Mark E Baker, Zhongya Wang, Leonardo Guizzetti, Lisa M Shackelton, Julie Rémillard, Mihir Patel, Jiafei Niu, Ronald Ottichilo, Cynthia S Santillan, Nunzia Capozzi, Stuart A Taylor, David Henry Bruining, Guangyong Zou, Brian G Feagan, Vipul Jairath, Jordi Rimola, null null
Reliability of CT Enterography for Describing Fibrostenosing Crohn Disease. Radiology 312 (2) (2024)
Sudheer Kumar Vuyyuru, Virginia Solitano, Siddharth Singh, Jurij Hanžel, John K Macdonald, Silvio Danese, Laurent Peyrin Biroulet, Christopher Ma, Vipul Jairath
Scoring Indices for Perianal Fistulising Crohn's Disease: A Systematic Review. Journal of Crohn's & colitis 18 (6) (2024)
Jurij Hanžel, Christopher Ma, Laurent Peyrin-Biroulet, Silvio Danese, Bruce E Sands, Vipul Jairath
Differences Between the 2016 and 2022 Food and Drug Administration Guidance-Implications for Design and Interpretation of Clinical Trials in Ulcerative Colitis. Crohn's & colitis 360 6 (2) (2024)
Sudheer Kumar Vuyyuru, Virginia Solitano, Siddharth Singh, Jurij Hanžel, John K Macdonald, Silvio Danese, Laurent Peyrin Biroulet, Christopher Ma, Vipul Jairath
Scoring Indices for Perianal Fistulising Crohn's Disease: A Systematic Review. Journal of Crohn's & colitis 18 (6) (2024)
Florian Rieders, Christopher Ma, Jurij Hanžel, Joel G Fletcher, Mark E Baker, Zhongya Wang, Leonardo Guizzetti, Lisa M Shackelton, Julie Rémillard, Mihir Patel, Jiafei Niu, Ronald Ottichilo, Cynthia S Santillan, Nunzia Capozzi, Stuart A Taylor, David Henry Bruining, Guangyong Zou, Brian G Feagan, Vipul Jairath, Jordi Rimola, null null
Reliability of CT Enterography for Describing Fibrostenosing Crohn Disease. Radiology 312 (2) (2024)
Jurij Hanžel, Christopher Ma, Vipul Jairath
Upadacitinib for the treatment of moderate-to-severe Crohn's disease. Immunotherapy (2024)
Florian Rieders, Christopher Ma, Jurij Hanžel, Joel G Fletcher, Mark E Baker, Zhongya Wang, Leonardo Guizzetti, Lisa M Shackelton, Julie Rémillard, Mihir Patel, Jiafei Niu, Ronald Ottichilo, Cynthia S Santillan, Nunzia Capozzi, Stuart A Taylor, David Henry Bruining, Guangyong Zou, Brian G Feagan, Vipul Jairath, Jordi Rimola, null null
Reliability of CT Enterography for Describing Fibrostenosing Crohn Disease. Radiology 312 (2) (2024)
Špela Pintar, Jurij Hanžel, David Drobne, Matic Koželj, Tina Kurent, Nataša Smrekar, Gregor Novak
Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease. Medicina (Kaunas, Lithuania) 60 (2) (2024)
Jurij Hanžel, Christopher Ma, Vipul Jairath
Upadacitinib for the treatment of moderate-to-severe Crohn's disease. Immunotherapy 16 (6) (2024)
Jurij Hanžel, Christopher Ma, Vipul Jairath
Upadacitinib for the treatment of moderate-to-severe Crohn's disease. Immunotherapy 16 (6) (2024)
Špela Pintar, Jurij Hanžel, David Drobne, Matic Koželj, Tina Kurent, Nataša Smrekar, Gregor Novak
Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease. Medicina (Kaunas, Lithuania) 60 (2) (2024)
Charlotte Wong, Joep van Oostrom, Valérie Pittet, Peter Bossuyt, Jurij Hanžel, Mark A Samaan, Monika Tripathi, Wladyslawa Czuber-Dochan, Burisch J, Salvatore Leone, Roberto Saldaña, Filip Baert, Uri Kopylov, Susanna Jaghult, Michel Adamina, Krisztina Gecse, Naila Arebi
Baseline Data and Measurement Instruments Reported in Observational Studies in Inflammatory Bowel Disease: Results from a Systematic Review. Journal of Crohn's & colitis 18 (6) (2024)
Jurij Hanžel, Christopher Ma, Laurent Peyrin-Biroulet, Silvio Danese, Bruce E Sands, Vipul Jairath
Differences Between the 2016 and 2022 Food and Drug Administration Guidance-Implications for Design and Interpretation of Clinical Trials in Ulcerative Colitis. Crohn's & colitis 360 6 (2) (2024)
Žan Peter Černe, Nejc Sever, Luka Strniša, Samo Plut, Jan Drnovšek, Jurij Hanžel, Darko Siuka, Borut Štabuc, David Drobne
Performance of European and American Societies of Gastrointestinal Endoscopy Guidelines for Prediction of Choledocholithiasis in Patients with Acute Biliary Pancreatitis. Medicina (Kaunas, Lithuania) 59 (12) (2023)
Jurij Hanžel, David Drobne
Editorial: golimumab dosing intensification effective in ulcerative colitis with no need for therapeutic drug monitoring. Alimentary pharmacology & therapeutics 57 (12) (2023)
Lotus Alphonsus, Theshani A De Silva, Christopher Ma, John K MacDonald, Jurij Hanžel, Melanie Beaton, Talat Bessissow, Maia Kayal, Rocio Sedano, Siddharth Singh, Vipul Jairath
Systematic review and meta-analysis of randomised controlled trials: Medical therapies for the treatment and prevention of pouchitis. Alimentary pharmacology & therapeutics (2023)
Žan Peter Černe, Nejc Sever, Luka Strniša, Samo Plut, Jan Drnovšek, Jurij Hanžel, Darko Siuka, Borut Štabuc, David Drobne
Performance of European and American Societies of Gastrointestinal Endoscopy Guidelines for Prediction of Choledocholithiasis in Patients with Acute Biliary Pancreatitis. Medicina (Kaunas, Lithuania) 59 (12) (2023)
Jurij Hanžel, Christopher Ma, Theshani Amalka De Silva, Lotus Alphonsus, Leonardo Guizzetti, Eileen Crowley, Siddharth Singh, Vipul Jairath
Approval Timelines for Advanced Therapeutics in Inflammatory Bowel Disease: A Comparison Between the European Medicines Agency and the Food and Drug Administration. Inflammatory bowel diseases (2023)
Sudheer Kumar Vuyyuru, Lisa M Shackelton, Jurij Hanžel, Christopher Ma, Vipul Jairath, Brian G Feagan
Targeting IL-23 for IBD: Rationale and Progress to Date. Drugs (2023)
Jurij Hanžel, Christopher Ma, Vipul Jairath
Mirikizumab for the treatment of moderate to severe ulcerative colitis. Immunotherapy (2023)
Jurij Hanžel, Vipul Jairath
A TIGER Among Endoscopic Indices in Inflammatory Bowel Disease. Journal of Crohn's & colitis 16 (4) (2022)
Jurij Hanžel, Laura H Bukkems, Krisztina B Gecse, Geert R D'Haens, Ron A A Mathôt
Editorial: subcutaneous CT-P13 in Crohn's disease and ulcerative colitis-small change, big consequences. Authors' reply. Alimentary pharmacology & therapeutics 55 (2) (2022)
Charlotte Wong, Joep van Oostrom, Peter Bossuyt, Valérie Pittet, Jurij Hanžel, Mark A Samaan, Monika Tripathi, Wladyslawa Czuber-Dochan, Johan Burisch, Salvatore Leone, Roberto Saldaña, Filip Baert, Uri Kopylov, Susanna Jaghult, Michel Adamina, Krisztina Gecse, Naila Arebi
A Narrative Systematic Review and Categorisation of Outcomes in Inflammatory Bowel Disease to Inform a Core Outcome Set for Real-world Evidence. Journal of Crohn's & colitis 16 (10) (2022)
Bella Ungar, Karin Malickova, Jurij Hanžel, Muhammad Abu Arisha, Stephane Paul, Catia Rocha, Zohar Ben Shatach, Chaya Mushka Abitbol, Ola Haj Natour, Limor Selinger, Miri Yavzori, Ella Fudim, Orit Picard, Irit Shoval, Rami Eliakim, Uri Kopylov, Fernando Magro, Xavier Roblin, Yehuda Chowers, David Drobne, Milan Lukas, Shomron Ben Horin
Dose optimisation for Loss of Response to Vedolizumab- Pharmacokinetics and Immune Mechanisms. Journal of Crohn's & colitis 15 (10) (2022)
Jurij Hanžel, David Drobne
Contemporary Management of Postoperative Crohn's Disease after Ileocolonic Resection. Journal of clinical medicine 11 (22) (2022)
Jurij Hanžel, Melanie S Hulshoff, Joep Grootjans, Geert R A M D'Haens
Emerging therapies for ulcerative colitis. Expert review of clinical immunology 18 (5) (2022)
Adriaan Volkers, Tessa Straatmijer, Marjolijn Duijvestein, Amber Sales, Amit Levran, Fiona van Schaik, P W Jeroen Maljaars, Krisztina Gecse, Cyriel Ponsioen, Joep Grootjans, Jurij Hanžel, Greetje Tack, Jeroen Jansen, Frank Hoentjen, Nanne de Boer, Sander van der Marel, Gerard Dijkstra, Bas Oldenburg, Mark Löwenberg, Andrea van der Meulen, Geert D Haens, null null
Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases. Alimentary pharmacology & therapeutics 56 (6) (2022)
Jurij Hanžel, Jeroen M Jansen, Rinze W F Ter Steege, Krisztina B Gecse, Geert R D'Haens
Multiple Switches From the Originator Infliximab to Biosimilars Is Effective and Safe in Inflammatory Bowel Disease: A Prospective Multicenter Cohort Study. Inflammatory bowel diseases (2021)
Jurij Hanžel, Erwin Dreesen, Séverine Vermeire, Mark Löwenberg, Frank Hoentjen, Peter Bossuyt, Esmé Clasquin, Filip J Baert, Geert R D'Haens, Ron Mathôt
Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD Study. Inflammatory bowel diseases (2021)
Jurij Aguiar Zdovc, Jurij Hanžel, Tina Kurent, Nejc Sever, Matic Koželj, Nataša Smrekar, Gregor Novak, Borut Štabuc, Erwin Dreesen, Debby Thomas, Tomaž Vovk, Barbara Ostanek, David Drobne, Iztok Grabnar
Ustekinumab Dosing Individualization in Crohn's Disease Guided by a Population Pharmacokinetic-Pharmacodynamic Model. Pharmaceutics 13 (10) (2021)
Jurij Hanžel, Laura H Bukkems, Krisztina B Gecse, Geert R D'Haens, Ron A A Mathôt
Population pharmacokinetics of subcutaneous infliximab CT-P13 in Crohn's disease and ulcerative colitis. Alimentary pharmacology & therapeutics 54 (10) (2021)
Jurij Hanžel, Vipul Jairath, Peter De Cruz, Leonardo Guizzetti, Lisa M Shackelton, Peter Bossuyt, Marjolijn Duijvestein, Parambir S Dulai, Johannes Grossmann, Robert P Hirten, Reena Khanna, Julian Panes, Laurent Peyrin-Biroulet, Miguel Regueiro, David T Rubin, Siddharth Singh, Ryan W Stidham, William J Sandborn, Brian G Feagan, Geert R D'Haens, Christopher Ma
Recommendations for Standardizing Clinical Trial Design and Endoscopic Assessment in Postoperative Crohn's Disease. Inflammatory bowel diseases (2021)
Jurij Hanžel, Christopher Ma, Niels Vande Casteele, Reena Khanna, Vipul Jairath, Brian G Feagan
Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease. Drugs 81 (3) (2021)
Jurij Hanžel, Nejc Sever, Ivan Ferkolj, Borut Štabuc, Nataša Smrekar, Tina Kurent, Matic Koželj, Gregor Novak, Griet Compernolle, Sophie Tops, Ann Gils, David Drobne
Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease. United European gastroenterology journal 7 (6) (2019)